Trendy Moderna's single-asset CF pact with Vertex marks a new phase of dealmaking
Just a few days after Moderna wrapped up a $200 million-upfront research deal with Merck, the Boston biotech is back with another pact – this …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
